Retroviral Integrase: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
==Function== | ==Function== | ||
[[Retroviral Integrase]] is an essential retroviral enzyme that binds to viral DNA and inserts it into a host cell chromosome. The reverse transcribed cDNA of human immunodeficiency virus type 1 (HIV-1) is inserted in the host cell genome in order increase pathogen fitness and virulence. Integrase is produced by a class of retrovirus (like HIV) and is used by the virus to incorporate its genetic material into the host cell DNA. The host cellular machinery then produces mRNA and then protein from the incorporated genetic material, thus replicating the virus. Although several integrase inhibiting drugs have been investigated, the mechanism responsible for strand-transfer inhibition action remains to be elucidated <ref>PMID:19915684</ref>. However, Hare el al (2010)<ref name=Hare_2010>PMID:20118915</ref> determined the structural constituents of retroviral integration. Further elucidation of the complete structure of the retroviral integrase, and its application to regulate functional and enzymatic activities could potentially enable researchers to delay the progression of retroviral diseases. Moreover, study of HIV-1 integration could lead to a promising new target, and contribute to the generation pharmacophore models for antiviral therapy<ref>deJesus, Edwin [http://www.thebody.com/content/art1352.html#ii HIV Antiretroviral Agents in Development]. The Body: The Complete HIV/AIDS Resource. March 30, 2006</ref>. <br/> | [[Retroviral Integrase]] is an essential retroviral enzyme that binds to viral DNA and inserts it into a host cell chromosome. The complex of integrase and DNA is called '''intasome.''' The reverse transcribed cDNA of human immunodeficiency virus type 1 (HIV-1) is inserted in the host cell genome in order increase pathogen fitness and virulence. Integrase is produced by a class of retrovirus (like HIV) and is used by the virus to incorporate its genetic material into the host cell DNA. The host cellular machinery then produces mRNA and then protein from the incorporated genetic material, thus replicating the virus. Although several integrase inhibiting drugs have been investigated, the mechanism responsible for strand-transfer inhibition action remains to be elucidated <ref>PMID:19915684</ref>. However, Hare el al (2010)<ref name=Hare_2010>PMID:20118915</ref> determined the structural constituents of retroviral integration. Further elucidation of the complete structure of the retroviral integrase, and its application to regulate functional and enzymatic activities could potentially enable researchers to delay the progression of retroviral diseases. Moreover, study of HIV-1 integration could lead to a promising new target, and contribute to the generation pharmacophore models for antiviral therapy<ref>deJesus, Edwin [http://www.thebody.com/content/art1352.html#ii HIV Antiretroviral Agents in Development]. The Body: The Complete HIV/AIDS Resource. March 30, 2006</ref>. <br/> | ||
HIV Integrase inhibitors: [http://www.isentress.com Raltegravir], marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007. | HIV Integrase inhibitors: [http://www.isentress.com Raltegravir], marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007. | ||
[See below for a table of antiretroviral drugs with trade name, company, patents, and notes.] | [See below for a table of antiretroviral drugs with trade name, company, patents, and notes.] | ||
| Line 19: | Line 19: | ||
[[Image:HIV_Stats.jpg|thumb|alt=Alt text|In 2010, there are more than 25 million people have died of AIDS, and it is estimated that approximately 33 million people are living with HIV.]] | [[Image:HIV_Stats.jpg|thumb|alt=Alt text|In 2010, there are more than 25 million people have died of AIDS, and it is estimated that approximately 33 million people are living with HIV.]] | ||
To date, more than 25 million people have died of AIDS and it is estimated that approximately 33 million people are living with HIV today<ref> [https://aidsinfo.nih.gov AIDS-Info]</ref>. For retroviral integrase inhibitors see [[Raltegravir]] and [[Retroviral Integrase Inhibitor Pharmacokinetics]]. | To date, more than 25 million people have died of AIDS and it is estimated that approximately 33 million people are living with HIV today<ref> [https://aidsinfo.nih.gov AIDS-Info]</ref>. For retroviral integrase inhibitors see [[Raltegravir]], [[Genvoya]] and [[Retroviral Integrase Inhibitor Pharmacokinetics]]. | ||
==Impact of Structure== | ==Impact of Structure== | ||
| Line 62: | Line 62: | ||
*<scene name='38/386179/Cv/3'>Zinc coordination site</scene>. | *<scene name='38/386179/Cv/3'>Zinc coordination site</scene>. | ||
*<scene name='38/386179/Cv/4'>K coordination site</scene>. | *<scene name='38/386179/Cv/4'>K coordination site</scene>. | ||
==Integrase Inhibitors== | ==Integrase Inhibitors== | ||
| Line 89: | Line 87: | ||
</StructureSection> | </StructureSection> | ||
==References== | ==References== | ||
